Goldman Sachs Group, Inc. (The) reaffirmed their neutral rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Thursday. Goldman Sachs Group, Inc. (The) currently has a $21.00 target price on the stock, down from their prior target price of $28.00.

A number of other analysts have also recently issued reports on the company. Cantor Fitzgerald restated a hold rating and set a $27.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. TheStreet cut Teva Pharmaceutical Industries Limited from a c- rating to a d+ rating in a research report on Friday, August 25th. Credit Suisse Group cut Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and lowered their price objective for the company from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Mizuho restated a neutral rating and set a $16.00 price objective (down from $30.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, August 22nd. Finally, BidaskClub cut Teva Pharmaceutical Industries Limited from a sell rating to a strong sell rating in a research report on Wednesday, August 16th. Four equities research analysts have rated the stock with a sell rating, twenty have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has an average rating of Hold and an average target price of $34.50.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 0.57% during trading on Thursday, reaching $15.95. The company had a trading volume of 12,603,411 shares. Teva Pharmaceutical Industries Limited has a 12 month low of $15.75 and a 12 month high of $52.66. The firm’s market capitalization is $16.21 billion. The stock has a 50 day moving average price of $23.63 and a 200 day moving average price of $29.88.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.25 earnings per share. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-receives-neutral-rating-from-goldman-sachs-group-inc-the/1536505.html.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.14%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

Institutional investors have recently added to or reduced their stakes in the stock. Capital Research Global Investors raised its position in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. raised its position in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the last quarter. FMR LLC raised its position in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the last quarter. Capital World Investors raised its position in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after buying an additional 2,782,257 shares during the last quarter. 56.87% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.